ReviewAcinetobacter baumannii: a universal threat to public health?
Introduction
Acinetobacter spp. have emerged in recent years as a major cause of nosocomial infections associated with significant morbidity and mortality [1], [2]. Considered to be a commensal of low-grade pathogenicity, i.e. an opportunistic microorganism, Acinetobacter was frequently ignored in the 1970s whenever isolated from clinical specimens [3]. However, interest in Acinetobacter has grown rapidly in the last 20 years, a fact attributed to: (i) the worldwide expansion of Intensive Care Units (ICUs) that led to a change in the type of infections caused by Acinetobacter; and (ii) the emergence of multidrug-resistant (MDR) strains, some of which nowadays are pan-resistant to antibiotics with the exception of colistin [4], [5], [6], [7], [8]. Developing resistance patterns have prompted the suggestion that we are closer to the end of the antibiotic era with Acinetobacter than with meticillin-resistant Staphylococcus aureus (MRSA) [9].
This review focuses on the epidemiology and resistance surveillance of Acinetobacter baumannii as well as current mechanisms of resistance and their clinical impact. In addition, current strategies in therapeutic efforts and control of this universal threat to public health are reviewed.
Section snippets
Taxonomy
Acinetobacter spp. are non-fermentative, strictly aerobic, non-motile, non-pigmented, catalase-positive and oxidase-negative Gram-negative coccobacilli, usually occurring in diploid formation or in chains of variable length that grow on usual laboratory media [10]. The taxonomic history of Acinetobacter spp. appears confusing since they have been classified variously, moving from the family Neisseriaceae to the family Moraxellaceae under the names Moraxella, Herellea, Mima, Achromobacter and
Global epidemiology
Acinetobacter baumannii has been recovered from soil, water, animals and humans, being ubiquitous in nature [13]. Acinetobacter spp. are normal inhabitants of the human skin in the community but are also frequently isolated from the respiratory tract of hospitalised patients [14]. Throat carriage may occur in up to 10% of community residents with excessive alcohol consumption [15]. It has been suggested that human skin could be the source of severe A. baumannii infections such as bacteraemia
Resistance surveillance and risk factors
Acinetobacter baumannii is nowadays emerging as a cause of numerous global outbreaks as well as an endemic strain in ICUs with rising resistance rates. MDR A. baumannii have been reported from hospitals in Europe, the USA, China, Hong Kong, Korea and Japan as well as from remote areas such as the South Pacific [2].
The British Society for Antimicrobial Chemotherapy (BSAC) surveillance data illustrate increasing resistance trends since 2002 in A. baumannii, with >30% of bacteraemic isolates in
Mechanisms of resistance
The recent emergence of A. baumannii strains multiresistant to many classes of antibiotics has been attributed to its rapid ability to accumulate resistance mechanisms as well as being well suited for genetic exchange. Therefore, Acinetobacter belongs to a unique class of Gram-negative bacteria that are characterised as ‘naturally transformable’ [2]. Recently, in a carbapenem-susceptible and extended-spectrum β-lactamase (ESBL)-producing A. baumannii clinical isolate, the largest antibiotic
The clinical impact of Acinetobacter infections
Nowadays, Acinetobacter has gained great interest owing to the worldwide emergence of MDR or even pan-resistant strains that either become endemic or suddenly cause outbreaks of infection, usually in ICUs [8], [87]. The occurrence in recent years of fulminant community-acquired as well as nosocomial pneumonia and VAP indicate the potential of Acinetobacter to cause invasive infections [1]. Like other Gram-negative bacilli, Acinetobacter produces a similar lipopolysaccharide that is responsible
Therapeutic approach
In March 2003, the Infectious Diseases Society of America (IDSA) established the Antimicrobial Availability Task Force (AATF), which prepared a report entitled ‘Bad bugs, no drugs. As antibiotic discovery stagnates… a public health crisis brews’, proposing potential solutions to the dreadful problem of decreasing antibiotic development [104].
The current particularly problematic MDR pathogens, as also identified by the AATF, are A. baumannii and Pseudomonas aeruginosa. Despite the fact that A.
Epilogue
Today, while clinicians confront the worst situation trying to combat even pan-resistant isolates such as Acinetobacter, the industry curtails the development of new antibiotics. A concerted effort by industry, government and academies is urgently required to improve the situation [6]. In the meantime, what is left for the clinician? Proper application of infection control measures and particularly of ‘hand hygiene’ as well as better antibiotic stewardship in order to slow the development of
References (149)
Clinical impact and pathogenicity of Acinetobacter
Clin Microbiol Infect
(2005)Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance
Clin Microbiol Infect
(2005)Resistance in nonfermenting Gram-negative bacteria: multidrug resistance to the maximum
Am J Med
(2006)- et al.
Antimicrobial resistance of Acinetobacter spp. in Europe
Clin Microbiol Infect
(2004) - et al.
Isolation of Acinetobacter spp. including A. baumannii from vegetables: implications for hospital-acquired infections
J Hosp Infect
(1999) - et al.
Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases
J Hosp Infect
(1999) - et al.
Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit
J Hosp Infect
(2004) - et al.
Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals
Res Microbiol
(2004) - et al.
Prevalence and antimicrobial patterns of A. baumannii on hands and nares of hospital personnel and patients: the iceberg phenomenon again
Heart Lung
(2002) - et al.
A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England
J Hosp Infect
(2004)
Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC program, 2002–2004
Diagn Microbiol Infect Dis
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004)
Clin Microbiol Infect
Greek System for Surveillance of Antimicrobial Resistance. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications
Clin Microbiol Infect
Importation of multidrug-resistant Acinetobacter spp. infections with casualties from Iraq
Lancet Infect Dis
Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature
J Hosp Infect
Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection
Clin Microbiol Infect
Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting
J Hosp Infect
Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study
Clin Microbiol Infect
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Clin Microbiol Infect
The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria
Clin Microbiol Infect
Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital
Diagn Microbiol Infect Dis
Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing Pseudomonas spp. and increase of IMP-producing Acinetobacter spp
Diagn Microbiol Infect Dis
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000)
Diagn Microbiol Infect Dis
Acinetobacter bacteremia in a teaching hospital, 1989–1998
Eur J Intern Med
Acinetobacter baumannii infections in the ICU: customization is the key
Chest
Global challenge of multidrug-resistant Acinetobacter baumannii
Antimicrob Agents Chemother
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features
Clin Microbiol Rev
Treatment options for multidrug-resistant bacteria
Expert Rev Anti Infect Ther
Acinetobacter baumannii: a threat for the ICU?
Intensive Care Med
The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting
Lett Appl Microbiol
Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative Gram-negative bacteria
Reliability of phenotypic tests for identification of Acinetobacter species
J Clin Microbiol
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
J Antimicrob Chemother
The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species
Clin Infect Dis
The epidemiology and control of Acinetobacter baumannii in health care facilities
Clin Infect Dis
Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups
J Clin Microbiol
Distribution of Acinetobacter species on skin of healthy humans
Eur J Clin Microbiol Infect Dis
Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant A. baumannii
Clin Infect Dis
Acinetobacter baumannii in human body louse
Emerg Infect Dis
Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004
MMWR Morb Mortal Wkly Rep
Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers
BMC Infect Dis
Survival of Acinetobacter baumannii on dry surfaces
J Clin Microbiol
Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates
J Clin Microbiol
An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment
JAMA
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units
J Hosp Infect
Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces
J Clin Microbiol
Endemic carbapenem-resistant Acinetobacter baumannii in a London hospital
J Antimicrob Chemother
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program, 2002–2004
Diagn Microbiol Infect Dis
In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals
Antimicrob Agents Chemother
Cited by (172)
An outbreak analysis of wound infection due to Acinetobacter baumannii in earthquake-trauma patients
2024, American Journal of Infection ControlAntibiotic therapy for nonfermenting Gram-negative bacilli infections: Future perspectives
2023, Current Opinion in Infectious Diseases